Scarica l'app Stockscreener
3.27
5.14%
0.16
Pre-mercato:
3.40
0.13
+3.98%
Precedente Chiudi:
$3.11
Aprire:
$3.3
Volume 24 ore:
2.37M
Relative Volume:
5.46
Capitalizzazione di mercato:
$47.61M
Reddito:
$1.03M
Utile/perdita netta:
$-13.40M
Rapporto P/E:
-2.4561
EPS:
-1.3314
Flusso di cassa netto:
$-10.27M
1 W Prestazione:
+49.32%
1M Prestazione:
+87.93%
6M Prestazione:
+77.72%
1 anno Prestazione:
+8.28%
Intervallo 1D:
$3.13
$3.78
Intervallo di 1 settimana:
$2.03
$3.78
Portata 52W:
$1.27
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
Nome
Dare Bioscience Inc
Settore
Industria
Telefono
858-926-7655
Indirizzo
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
3.27 | 47.61M | 1.03M | -13.40M | -10.27M | -1.3314 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dare Bioscience Inc Borsa (DARE) Ultime notizie
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Dare Bioscience | DEFA14A: Others - Moomoo
Form ARS Dare Bioscience, Inc. For: Dec 31 - StreetInsider
Daré Bioscience (DARE) seeks approval for Lincoln Park share facility and 1.5M-plan increase - Stock Titan
Daré outlines expanded dual path strategy targeting $4.5B hormone therapy market while accelerating commercialization in Q4 2025 - MSN
Dare Bioscience FY 2025 earnings preview - MSN
Daré Bioscience Posts Updated Corporate Investor Presentation Online - The Globe and Mail
Daré Bioscience (DARE) posts updated corporate investor presentation - Stock Titan
Dare Bioscience completes closing of Regulation A offering of preferred stock and warrants - Investing.com UK
Daré Bioscience Completes Regulation A Preferred Stock Offering - TipRanks
Daré Bioscience (NASDAQ: DARE) closes 20,000-unit Regulation A sale - Stock Titan
DARE Surges As Daré Bioscience Unveils Women’s Health Catalysts - StocksToTrade
DARE Surges As Daré Bioscience Launches Women’s Sildenafil Cream - timothysykes.com
DARE Bioscience Jumps As DARE to PLAY Launch and Pipeline Catalysts Draw Focus - StocksToTrade
DARE Bioscience Jumps As DARE to PLAY Launch Highlights Catalyst Path - timothysykes.com
Daré Bioscience Rebalances Classified Board Structure and Terms - TipRanks
Daré Bioscience (DARE) reclassifies director to rebalance staggered board - Stock Titan
Daré Bioscience (NASDAQ: DARE) asks shareholders to approve 1.5M plan shares, vote June 11 - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
DARE Technical Analysis | Trend, Signals & Chart Patterns | DARE BIOSCIENCE INC (NASDAQ:DARE) - ChartMill
Dare Bioscience completes closing of Regulation A equity offering By Investing.com - Investing.com Australia
DARÉ BIOSCIENCE, INC. Files Form 8-K Report with SEC for Unregistered Sales of Equity Securities – April 2026 - Minichart
Dare Bioscience completes closing of Regulation A equity offering - Investing.com
Daré Bioscience (NASDAQ: DARE) closes Regulation A sale of 3,470 units - Stock Titan
Maxim Group Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $8 - Moomoo
LEXX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Head-To-Head Review: Dare Bioscience (NASDAQ:DARE) & Appili Therapeutics (OTCMKTS:APLIF) - Defense World
Maxim Group Upgrades Daré Bioscience (DARE) - MSN
Dare Bioscience | QUALIF: Others - Moomoo
Dare Bioscience, Inc. (DARE) reports Q4 loss, lags revenue estimates - MSN
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Dare Bioscience Q4 2025 Earnings Call Transcript - MarketBeat
Transcript : Daré Bioscience, Inc., 2025 Earnings Call, Mar 26, 2026 - marketscreener.com
Dare Bioscience, Inc. (DARE) Announces Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
Dare Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Earnings call transcript: Daré Bioscience Q4 2025 highlights capital efficiency By Investing.com - Investing.com India
Earnings call transcript: Daré Bioscience Q4 2025 highlights capital efficiency - Investing.com
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Daré Bioscience, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:DARE) 2026-03-26 - Seeking Alpha
Q4 2025 Dare Bioscience Inc Earnings Call Transcript - GuruFocus
Daré Bioscience (NASDAQ: DARE) expands dual-path women’s health model - Stock Titan
Daré Bioscience (NASDAQ: DARE) details 2025 loss, funding boost and upcoming product launches - stocktitan.net
DARE: DARE to PLAY launches nationwide, with multi-product revenue growth expected in 2026-2027 - TradingView
Dare Bioscience Inc (DARE) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Dare Bioscience Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
A Viagra ingredient is now in a topical cream developed for women - Stock Titan
On National Viagra Day, Women Finally Claim Their Turn: - Bitget
Dare Bioscience (DARE) Expected to Announce Earnings on Monday - Defense World
Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026 - The Manila Times
Dare Bioscience Inc Azioni (DARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):